Revenue remains highly intermittent and negligible, with the company generating only $183,000 in the most recent period of activity while maintaining high fixed costs.
| Sales/Revenue | 183K | 183K | 122K | 2.03M | 480K | 2.2M | 1.69M |
| Revenue Growth % | 50% | 50% | -93.99% | 322.71% | -78.19% | 30.62% | - |
| Cost of Goods Sold | 284K | 0 | 0 | 9.75M | 8.63M | 1.52M | 1.71M |
| COGS % of Revenue | - | - | - | 480.73% | 1797.29% | 69.29% | 101.66% |
| Gross Profit | -101K | 183K | 122K | -7.72M | -8.15M | 676K | -28K |
| Gross Margin % | -55.19% | 100% | 100% | -380.73% | -1697.29% | 30.71% | -1.66% |
| Gross Profit Growth % | - | 50% | 101.58% | 5.18% | -1305.18% | 2514.29% | - |
| Operating Expenses | 14.59M | 10.1M | 11.87M | 8.96M | 6.83M | 13.03M | 5.35M |
| OpEx % of Revenue | - | 5521.31% | 9727.87% | 441.6% | 1422.92% | 592.14% | 317.39% |
| Selling, General & Admin | 10.73M | 7.12M | 7.6M | 8.96M | 6.83M | 6.93M | 4.22M |
| SG&A % of Revenue | - | 3891.26% | 6231.15% | 441.6% | 1422.92% | 314.86% | 250.45% |
| Research & Development | 881K | 2.98M | 4.27M | 9.75M | 8.63M | 6.1M | 1.13M |
| R&D % of Revenue | - | 1630.05% | 3496.72% | 480.73% | 1797.29% | 277.28% | 66.94% |
| Other Operating Expenses | 1000K | 0 | 0 | -9.75M | -8.63M | 31K | 0 |
| Operating Income | -14.55M | -9.92M | -11.75M | -16.68M | -14.98M | -12.36M | 5.38M |
| Operating Margin % | -7950.82% | -5421.31% | -9627.87% | -822.33% | -3120.21% | -561.43% | 319.05% |
| Operating Income Growth % | - | 15.54% | 29.6% | -11.4% | -21.2% | -329.85% | - |
| EBITDA | -11.3M | -9.3M | -10.95M | -15.83M | -14.45M | -12.2M | 5.44M |
| EBITDA Margin % | -6174.32% | -5081.42% | -8978.69% | -780.14% | -3011.25% | -554.34% | 322.85% |
| EBITDA Growth % | 34.37% | 15.11% | 30.8% | -9.51% | -18.47% | -324.28% | - |
| D&A (Non-Cash Add-back) | 436K | 622K | 792K | 856K | 523K | 156K | 64K |
| EBIT | -12.6M | -6.84M | -11.68M | -16.64M | -14.98M | -12.36M | -6.04M |
| Net Interest Income | -1.4M | -378K | 40K | -200K | -17K | 0 | 0 |
| Interest Income | 30K | 9K | 63K | 48K | 0 | 0 | 0 |
| Interest Expense | 1.49M | 387K | 23K | 248K | 17K | 0 | 69K |
| Other Income/Expense | 454K | 2.69M | 40K | -200K | 242K | 31K | -11.48M |
| Pretax Income | -14.1M | -7.23M | -11.71M | -16.89M | -14.73M | -12.33M | -6.11M |
| Pretax Margin % | -7702.19% | -3951.91% | -9595.08% | -832.18% | -3069.79% | -560.02% | -362.55% |
| Income Tax | -57.97K | 0 | 0 | 330K | 0 | 31K | -595K |
| Effective Tax Rate % | 0.41% | 0% | 0% | -1.95% | 0% | -0.25% | 9.74% |
| Net Income | -14.04M | -7.23M | -11.71M | -17.21M | -14.73M | -12.36M | -5.51M |
| Net Margin % | -7670.49% | -3951.91% | -9595.08% | -848.45% | -3069.79% | -561.43% | -327.24% |
| Net Income Growth % | 15.82% | 38.22% | 32% | -16.83% | -19.24% | -124.1% | - |
| Net Income (Continuing) | -14.04M | -7.23M | -11.71M | -17.21M | -14.73M | -12.36M | -5.51M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 549K | 549K | 549K | 549K | 549K | 0 | 0 |
| EPS (Diluted) | -5.37 | -23.10 | -37.50 | -55.50 | -47.70 | -31.50 | -14.10 |
| EPS Growth % | 58.67% | 38.4% | 32.43% | -16.35% | -51.43% | -123.4% | - |
| EPS (Basic) | - | -23.10 | -37.50 | -55.50 | -47.70 | -31.50 | -14.10 |
| Diluted Shares Outstanding | 2.61M | 313.27K | 311.9K | 310.4K | 309.13K | 392.2K | 387.93K |
| Basic Shares Outstanding | 2.61M | 313.27K | 311.9K | 310.4K | 309.13K | 392.2K | 387.93K |
| Dividend Payout Ratio | - | - | - | - | - | - | - |
Imminent liquidity insolvency risk
As reported in financial statements, Abpro's revenue remains highly intermittent and negligible, with the company generating only $183,000 in the most recent period of activity, underscoring a reliance on sporadic milestone payments rather than a scalable, recurring commercial model capable of supporting ongoing research and development operations.
The absence of consistent top-line growth suggests that the company has yet to achieve a repeatable commercialization phase for its DiversImmune platform. Investors should monitor the reliance on non-recurring service fees, which appear insufficient to offset the substantial operating expenses required for clinical-stage biotechnology development.
Based on reported figures, Abpro maintains a high-fixed-cost structure characterized by significant R&D and SG&A expenditures that consistently dwarf nominal revenue inflows, creating a structural disconnect that necessitates frequent external capital infusions to sustain the company's current clinical trial trajectory and specialized personnel requirements.
The company's cost structure is dominated by research-related outflows, which appear to be scaling without a corresponding increase in partnership-driven revenue. This imbalance suggests that the firm is currently operating in a high-burn environment where expense discipline is secondary to the urgent need for clinical milestone achievement.
According to recent SEC filings, Abpro's operating income remains deeply negative, with quarterly losses frequently exceeding $2 million, indicating that the company has not yet achieved the operational scale necessary to leverage its fixed cost base or move toward a sustainable path to profitability.
The lack of operating leverage is a direct consequence of the company's pre-commercial status and the heavy investment required for its oncology programs. Without a significant shift in revenue volume, the current operating model appears to be structurally incapable of scaling efficiently, leaving the firm highly sensitive to capital market conditions.
As indicated by the company's financial data, the current cash position of $2.85 million against multi-million dollar quarterly operating losses suggests a precarious liquidity profile that may force highly dilutive financing events or indicate a potential going concern risk in the near-term future for shareholders.
Short-term investors should be wary of the disconnect between the company's long-term platform potential and its immediate liquidity constraints. The reliance on external funding to bridge the gap between research and commercialization creates a binary outcome where the company's survival is contingent upon securing new partnerships or capital before existing reserves are depleted.
Quick answers to the most common questions about buying ABP stock.
For fiscal year 2024, Abpro Corporation (ABP) reported total revenue of $0.2M. This represents a 89.1% decline compared to $1.7M in 2016.
Abpro Corporation (ABP) reported a net loss of $7.2M for the fiscal year ending 2024.
Abpro Corporation (ABP) reported an operating income of $-9.9M, resulting in an operating profit margin of -5421.3%. This margin reflects the operational efficiency of the business before interest and taxes.
Abpro Corporation (ABP) generated $0.2M in gross profit for the year, representing a gross profit margin of 100.0%. This demonstrates the company's core pricing power and production efficiency.